Home › Funds › Lion Point Capital, LP › SNDX
Lion Point Capital, LP position in SNDX
SYNDAX PHARMACEUTICALS INC · Health Care
Lion Point Capital, LP reported holding 36,000 shares of SNDX (SYNDAX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$787K, representing 3.76% of its reported portfolio and ranking #9 among its reported holdings. Lion Point Capital, LP has disclosed SNDX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Lion Point Capital, LP's SNDX position evolved
Lion Point Capital, LP first disclosed a stake in SNDX in Q3 2023 at 34,500 shares (US$501K). The position peaked in Q1 2024 at 65,000 shares, worth US$1.5M. Across 12 filings, Lion Point Capital, LP increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 7 time(s). The most recent filing (Q2 2026) shows 36,000 shares valued at US$787K. Notable position changes include a 88% increase in Q1 2024 (shares fell 14% over the following quarter), a 29% trim in Q3 2024 (shares fell 31% over the following quarter), a 35% trim in Q4 2025 (shares rose 11% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 34.50K | $500.94K | New |
| Q4 2023 | 34.50K | $745.54K | Hold |
| Q1 2024 | 65.00K | $1.55M | Add |
| Q2 2024 | 65.00K | $1.33M | Hold |
| Q3 2024 | 46.20K | $889.35K | Reduce |
| Q4 2024 | 55.00K | $727.10K | Add |
| Q1 2025 | 55.00K | $675.67K | Hold |
| Q2 2025 | 55.00K | $515.08K | Hold |
| Q3 2025 | 55.00K | $846.17K | Hold |
| Q4 2025 | 36.00K | $756.36K | Reduce |
| Q1 2026 | 36.00K | $840.96K | Hold |
| Q2 2026 | 36.00K | $786.96K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SNDX and 13F data
SNDX (SYNDAX PHARMACEUTICALS INC) is a Health Care company. 43 other funds we track also report a position in SNDX — the largest reported positions include Kynam Capital Management, LP (US$176.0M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$82.6M), Eversept Partners, LP (US$61.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SNDX
- Kynam Capital Management, LP 8.05M sh · $175.99M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.78M sh · $82.63M · Q2 2026
- Eversept Partners, LP 2.80M sh · $61.17M · Q2 2026
- KINGDON CAPITAL MANAGEMENT, L.L.C. 2.50M sh · $54.65M · Q2 2026
- Elmind Capital, LP 1.85M sh · $40.55M · Q2 2026
- Soleus Capital Management, L.P. 1.63M sh · $35.59M · Q2 2026
- ORBIMED ADVISORS LLC 1.54M sh · $33.71M · Q2 2026
- MPM BioImpact LLC 1.33M sh · $29.15M · Q2 2026
- Aisling Capital Management LP 1.32M sh · $28.79M · Q2 2026
- Catalio Capital Management, LP 1.22M sh · $26.58M · Q2 2026
- Prosight Management, LP 1.20M sh · $26.23M · Q2 2026
- Trails Edge Capital Partners, LP 1.11M sh · $24.26M · Q2 2026
More on Lion Point Capital, LP
FAQ
How long has Lion Point Capital, LP held SNDX?
Lion Point Capital, LP has disclosed SNDX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Lion Point Capital, LP's current position in SNDX?
As of Q2 2026, Lion Point Capital, LP holds 36.00K shares of SNDX (SYNDAX PHARMACEUTICALS INC), valued at $786.96K, representing 3.76% of its reported portfolio and ranking #9.
Has Lion Point Capital, LP been buying or selling SNDX?
In the latest 13F filing (Q2 2026), Lion Point Capital, LP held unchanged its position in SNDX. The position peaked in Q1 2024 at 65.00K shares.
Which other funds hold SNDX?
Other major institutional holders of SNDX include Kynam Capital Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Eversept Partners, LP, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.